J&J Nevo Stent Inhibits Tissue Proliferation Better Than Boston Sci’s Liberté
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis' Nevo next-generation sirolimus-eluting coronary stent inhibits tissue proliferation better than Boston Scientific's Taxus Liberté paclitaxel-eluting stent at six months, according to data from the NEVO RES-Elution I study unveiled May 19 at the EuroPCR meeting in Barcelona
You may also be interested in...
J&J Temporarily Halts Nevo Stent Trial, Citing Needed Catheter Improvements
Johnson & Johnson has suspended enrollment in its NEVO II trial comparing its next-generation Nevo stent to Abbott's market-leading Xience V stent, citing needed improvements to the balloon catheter component of the system, the firm announced Oct. 19.
J&J Temporarily Halts Nevo Stent Trial, Citing Needed Catheter Improvements
Johnson & Johnson has suspended enrollment in its NEVO II trial comparing its next-generation Nevo stent to Abbott's market-leading Xience V stent, citing needed improvements to the balloon catheter component of the system, the firm announced Oct. 19.
EuroPCR In Brief
MitraClip: Abbott's transcatheter mitral valve repair device kept well within the non-inferiority margin compared to surgery on the composite endpoint of freedom from death, from follow-up mitral valve surgery and from greater-than-mild mitral regurgitation after two years of follow-up, EVEREST II trial investigator Ted Feldman, M.D., NorthShore University Health System, reported May 25 at the EuroPCR conference in Paris. And in a one-year subgroup analysis, there was no statistical difference in safety and similar efficacy outcome in MitraClip patients with either functional or degenerative mitral regurgitation, he said. MitraClip attracted significant attention in March when Feldman reported it has met its one-year non-inferiority efficacy endpoint and 30-day superiority safety endpoint versus open surgery at the American College of Cardiology annual meeting (1"The Gray Sheet" March 22, 2010). The EuroPCR MR subgroup analysis is particularly important, said Michael Weinstein, a J.P. Morgan analyst, because it "suggests that Abbott will be able to target the entire [MR] market, significantly increasing the potential opportunity.